Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab)
Cancer is a leading cause of death in CA. Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). Discovered a protein, ROR1, present on CSCs but not on normal healthy cells. Developed an antibody, cirmtuzumab, that is specific for ROR1. Project plan is to treat chronic lymphocytic leukemia with cirmtuzumab.
Open label, single arm study.
Safety. Dosing. Follow on trials will include other cancers and will test cirmtuzumab alone or in combination with other anti-cancer therapies.